Under an agreement announced Monday, Feb. 23, Organon will pay $27.5 million upfront for the right to market Sebela’s Miudella, billed as the first FDA-approved device of its kind in 40 years.
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results